Literature DB >> 23636036

Perennial is more effective than preseasonal subcutaneous immunotherapy in the treatment of seasonal allergic rhinoconjunctivitis.

Damian Tworek1, Malgorzata Bochenska-Marciniak, Izabela Kuprys-Lipinska, Maciej Kupczyk, Piotr Kuna.   

Abstract

BACKGROUND: Two different regimens of subcutaneous immunotherapy (IT), perennial or preseasonal, may be used in the treatment of seasonal allergy. The aim of this study was to compare the efficacy and safety of perennial IT (PIT) and preseasonal IT (PSIT) in patients suffering from seasonal rhinoconjunctivitis.
METHODS: The study was planned as a randomized, double-blind, comparative study on the efficacy and safety of PIT and PSIT. The study group comprised 120 patients allergic to grass and rye pollen. After the observational season they were randomized to receive PIT or PSIT for 3 years. The effect of IT was assessed based on symptom severity and medication use recorded in diaries.
RESULTS: Ninety-nine patients completed the study. No difference was seen between the groups regarding combined symptom medication score (SMS) in the first season of IT. During the second season, the difference between PIT and PSIT regarding combined SMS was 27.9% (p = 0.063) and reached 42.7% (p = 0.012) in favor of PIT in the third season. Both treatments had a similar safety profile.
CONCLUSION: PIT was more effective than PSIT in the treatment of rhinoconjunctivitis in patients allergic to grass and rye pollens.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636036      PMCID: PMC3711679          DOI: 10.2500/ajra.2013.27.3935

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  15 in total

1.  One hundred years of immunotherapy: review of the first landmark studies.

Authors:  Désirée E S Larenas Linnemann
Journal:  Allergy Asthma Proc       Date:  2012 Mar-Apr       Impact factor: 2.587

2.  Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity.

Authors:  M J Furin; P S Norman; P S Creticos; D Proud; A Kagey-Sobotka; L M Lichtenstein; R M Naclerio
Journal:  J Allergy Clin Immunol       Date:  1991-07       Impact factor: 10.793

3.  Comparison of 2 maintenance doses (100 microg vs 200 microg) in Hymenoptera venom immunotherapy: influence of the maintenance dose on the immunologic response.

Authors:  Jean-Charles Glérant; Philippe Martinez; Claude Guillaume; Vincent Jounieaux
Journal:  Ann Allergy Asthma Immunol       Date:  2005-04       Impact factor: 6.347

Review 4.  Immunological mechanisms of allergen-specific immunotherapy.

Authors:  Marek Jutel; C A Akdis
Journal:  Allergy       Date:  2011-04-06       Impact factor: 13.146

5.  Long-term efficacy of preseasonal grass pollen immunotherapy in children.

Authors:  P A Eng; M Reinhold; H P E Gnehm
Journal:  Allergy       Date:  2002-04       Impact factor: 13.146

Review 6.  The risk and management of anaphylaxis in the setting of immunotherapy.

Authors:  Phil Lieberman
Journal:  Am J Rhinol Allergy       Date:  2012 Nov-Dec       Impact factor: 2.467

7.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

Authors:  Christian Möller; Sten Dreborg; Hosne A Ferdousi; Susanne Halken; Arne Høst; Lars Jacobsen; Antti Koivikko; Dieter Y Koller; Bodo Niggemann; Lene A Norberg; Radvan Urbanek; Erkka Valovirta; Ulrich Wahn
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

8.  Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study.

Authors:  G B Pajno; G Barberio; F De Luca; L Morabito; S Parmiani
Journal:  Clin Exp Allergy       Date:  2001-09       Impact factor: 5.018

Review 9.  Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce.

Authors:  G W Canonica; C E Baena-Cagnani; J Bousquet; P J Bousquet; R F Lockey; H-J Malling; G Passalacqua; P Potter; E Valovirta
Journal:  Allergy       Date:  2007-03       Impact factor: 13.146

10.  Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study.

Authors:  S M Walker; V A Varney; M Gaga; M R Jacobson; S R Durham
Journal:  Allergy       Date:  1995-05       Impact factor: 13.146

View more
  6 in total

1.  Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach.

Authors:  Ann-Kathrin Richter; Ludger Klimek; Hans F Merk; Norbert Mülleneisen; Harald Renz; Wolfgang Wehrmann; Thomas Werfel; Eckard Hamelmann; Uwe Siebert; Gaby Sroczynski; Jürgen Wasem; Janine Biermann-Stallwitz
Journal:  Eur J Health Econ       Date:  2018-03-24

2.  [Specific immunotherapy].

Authors:  S A Grundmann; P Mosters; R Brehler
Journal:  Hautarzt       Date:  2014-07       Impact factor: 0.751

3.  Subcutaneous Immunotherapy Improves the Symptomatology of Allergic Rhinitis.

Authors:  Edmir Américo Lourenço; Eduardo José Caldeira; César Alexandre Fabrega Carvalho; Marcelo Rodriques Cunha; Marcus Vinícius Henriques Carvalho; Saulo Duarte Passos
Journal:  Int Arch Otorhinolaryngol       Date:  2015-10-07

4.  Patients' compliance with different administration routes for allergen immunotherapy in Germany.

Authors:  Anne-Marie Egert-Schmidt; Jan-Marcel Kolbe; Sabine Mussler; Susanne Thum-Oltmer
Journal:  Patient Prefer Adherence       Date:  2014-10-24       Impact factor: 2.711

5.  The efficacy assessment of a self-administered immunotherapy protocol.

Authors:  Frederick M Schaffer; Larry M Garner; Myla Ebeling; Jeffrey M Adelglass; Thomas C Hulsey; Andrew R Naples
Journal:  Int Forum Allergy Rhinol       Date:  2015-10-14       Impact factor: 3.858

6.  Induction of Bronchial Tolerance After 1 Cycle of Monophosphoryl-A-Adjuvanted Specific Immunotherapy in Children With Grass Pollen Allergies.

Authors:  Martin Rosewich; Katharina Girod; Stefan Zielen; Ralf Schubert; Johannes Schulze
Journal:  Allergy Asthma Immunol Res       Date:  2016-05       Impact factor: 5.764

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.